Trump Just Signed the Biggest Executive Order Ever — Asmongold Breaks Down the Drug Pricing Move

In a live reaction stream, Asmongold and his co-host analyze what they describe as potentially the most consequential executive order of Donald Trump's presidency — a directive aimed at forcing pharmaceutical companies to charge Americans the lowest price they offer to any other country. The conversation centers on whether this is real policy change or political theater, and what it means for the broader healthcare system.

The Core Argument: Most Favored Nation Pricing for Drugs

The executive order Trump is signing would implement what the hosts call the "Manjione mandate" — a reference to the diabetes drug Mounjaro, which Trump used as an example during his remarks. The principle is simple: the United States would pay no more for any prescription drug than the lowest price that drug is sold for in any other developed country. Trump claimed that Americans currently pay 75% of big pharma's global profits despite being only 5% of the world's population, and cited a personal anecdote about a wealthy businessman friend who pays $88 for the same weight-loss drug in London that costs $1,300 in New York.